연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2024년 | 2023년 | 2022년 | 2021년 | 2020년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 179편 | 173편 | 163편 | 184편 | 135편 |
| 공동 | 147편 | 120편 | 115편 | 136편 | 168편 | |
| 합계 | 326편 | 293편 | 278편 | 320편 | 303편 | |
3517. Recycled polyethylene terephthalate/ FeCo@C/ Silver nanowire/ polyimide sandwich membrane for electrothermal heating and electromagnetic interference shielding
Shuqing Piao, Zhuomin Jiang, Shengjun Li, Taewook Park, Yonghwan Kim, Eunji Lee, Sohui Lee, Sun Ha Paek, Jungsuek Oh, Hyung-Jun Im, Wang Zhang, Kangwon Lee, Yuanzhe Piao
JOURNAL OF ALLOYS AND COMPOUNDS. 2024 JUN 5;987:174256(1-12)
3516. Multifunctional Ultrathin Recycled PET-Based Membrane for Electromagnetic Interference Shielding, Antibacterial and Thermal Management
Zhuomin Jiang, Shuqing Piao, Taewook Park, Shengjun Li, Yonghwan Kim, Eunji Lee, Chaewon Bae, Yejin Lee, Hyung‐Jun Im, Jungsuek Oh, Yuanzhe Piao, Kangwon Lee
ADVANCED MATERIALS INTERFACES. 2024 Feb 05;11(14):2301047(1-12)
3515. A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial
Hortobagyi GN, Lacko A, Sohn J, Cruz F, Ruiz Borrego M, Manikhas A, Hee Park Y, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Martin M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Parnizari F, Zarate JP, Li Z, Waters S, Chakravartty A, Slamon D
Annals of oncology 2024 Oct 21 [Epub ahead of print]
Link
3514. Prediction of menstrual recovery patterns in premenopausal women with breast cancer taking tamoxifen after chemotherapy: an ASTRRA Substudy
Lee YJ, Noh WC, Gwark S, Kim HA, Ryu JM, Kim SI, Lee EG, Im SA, Jung Y, Park MH, Park KH, Kang SH, Jeong J, Park E, Kim SY, Lee MH, Kim LS, Lim W, Kim S, Kim HJ
Breast cancer research 2024 Nov 5;26(1):152.
Link
3513. Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer
Turner NC, Im SA, Saura C, Juric D, Loibl S, Kalinsky K, Schmid P, Loi S, Sunpaweravong P, Musolino A, Li H, Zhang Q, Nowecki Z, Leung R, Thanopoulou E, Shankar N, Lei G, Stout TJ, Hutchinson KE, Schutzman JL, Song C, Jhaveri KL
The New England journal of medicine 2024 Oct 31;391(17):1584-1596.
Link
3512. Sacituzumab govitecan in HR+HER2- metastatic breast cancer: the randomized phase 3 EVER-132-002 trial
Xu B, Wang S, Yan M, Sohn J, Li W, Tang J, Wang X, Wang Y, Im SA, Jiang D, Valdez T, Dasgupta A, Zhang Y, Yan Y, Komatsubara KM, Chung WP, Ma F, Dai MS
Nature medicine 2024 Dec;30(12):3709-3716
Link
3511. Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
Jhaveri KL, Lim E, Jeselsohn R, Ma CX, Hamilton EP, Osborne C, Bhave M, Kaufman PA, Beck JT, Manso Sanchez L, Parajuli R, Wang HC, Tao JJ, Im SA, Harnden K, Yonemori K, Dhakal A, Neven P, Aftimos P, Yves-Pierga J, Lu YS, Larson T, Jerez Y, Sideras K, Sohn J, Kim SB, Saura C, Bardia A, Sammons SL, Bacchion F, Li Y, Yuen E, Estrem ST, Rodrik-Outmezguine V, Nguyen B, Ismail-Khan R, Smyth L, Beeram M
Journal of clinical oncology 2024 Dec 10;42(35):4173-4186
Link
3510. BRCA genetic testing and counseling in breast cancer: how do we meet our patients' needs?
Dubsky P, Jackisch C, Im SA, Hunt KK, Li CF, Unger S, Paluch-Shimon S
NPJ breast cancer 2024 Sep 5;10(1):77
Link
3509. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01
Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Xu L, Fairhurst RM, Khan S, Denduluri N, Rugo HS, Xu B, Pistilli B
Journal of clinical oncology 2024 Sep 12 [Epub ahead of print]
Link
3508. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kümmel S, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Im SA, Untch M, Fasching PA, Mouret-Reynier MA, Foukakis T, Ferreira M, Cardoso F, Zhou X, Karantza V, Tryfonidis K, Aktan G, O'Shaughnessy J
The New England journal of medicine 2024 Nov 28;391(21):1981-1991
Link